Oscar Health, Inc. (NYSE:OSCR) Director Thrive Partners Vii Growth Gp, Purchases 420,819 Shares

Oscar Health, Inc. (NYSE:OSCR) Director Thrive Partners Vii Growth Gp, acquired 420,819 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was bought at an average price of $13.68 per share, with a total value of $5,756,803.92. Following the completion of the acquisition, the director now directly owns 5,452,081 shares of the company’s stock, valued at approximately $74,584,468.08. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Oscar Health Stock Down 0.6 %

Shares of Oscar Health stock opened at $13.48 on Thursday. Oscar Health, Inc. has a 12-month low of $6.93 and a 12-month high of $23.79. The firm has a market capitalization of $3.26 billion, a PE ratio of -224.63, a price-to-earnings-growth ratio of 12.49 and a beta of 1.67. The company has a quick ratio of 0.91, a current ratio of 0.73 and a debt-to-equity ratio of 0.26. The stock’s fifty day moving average is $18.28 and its 200-day moving average is $18.30.

Oscar Health (NYSE:OSCR) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.02). Oscar Health had a return on equity of 2.79% and a net margin of 0.35%. The company had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.33 billion. During the same quarter in the previous year, the firm posted ($0.29) EPS. Oscar Health’s quarterly revenue was up 68.3% on a year-over-year basis. Equities analysts anticipate that Oscar Health, Inc. will post -0.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

OSCR has been the subject of a number of research reports. Piper Sandler reaffirmed an “overweight” rating and set a $28.00 price target on shares of Oscar Health in a research note on Tuesday, September 10th. UBS Group assumed coverage on Oscar Health in a research note on Monday, October 7th. They set a “neutral” rating and a $23.00 target price for the company. Finally, Bank of America cut shares of Oscar Health from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $21.00 to $13.50 in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.93.

Institutional Investors Weigh In On Oscar Health

Several hedge funds have recently made changes to their positions in OSCR. Versor Investments LP acquired a new position in Oscar Health during the third quarter valued at $787,000. Assenagon Asset Management S.A. increased its holdings in shares of Oscar Health by 32.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,046,046 shares of the company’s stock valued at $32,368,000 after purchasing an additional 507,009 shares during the period. FCG Investment Co purchased a new stake in shares of Oscar Health in the third quarter worth approximately $986,000. Jupiter Asset Management Ltd. acquired a new stake in shares of Oscar Health during the first quarter worth approximately $653,000. Finally, Toth Financial Advisory Corp grew its position in Oscar Health by 73,185.7% during the third quarter. Toth Financial Advisory Corp now owns 51,300 shares of the company’s stock valued at $1,088,000 after purchasing an additional 51,230 shares in the last quarter. Hedge funds and other institutional investors own 75.70% of the company’s stock.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.